Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1821583 | 0.89 | MDM2 (0.69) | MDM2 | |
| SCHEMBL20100138 | 0.86 | MDM2 (0.74) | MDM2 | |
| SCHEMBL1823246 | 0.85 | MDM2 (0.70) | MDM2 | |
| SCHEMBL1820534 | 0.85 | MDM2 (1.00) | MDM2 | |
| SCHEMBL1824231 | 0.83 | MDM2 (0.72) | MDM2 | |
| SCHEMBL12332981 | 0.83 | MDM2 (0.73) | MDM2 | |
| SCHEMBL12333073 | 0.79 | MDM2 (0.89) | MDM2 | |
| SCHEMBL20100104 | 0.79 | MDM2 (0.76) | MDM2 | |
| SCHEMBL21539805 | 0.79 | MDM2 (0.79) | MDM2 | |
| SCHEMBL4914548 | 0.79 | MDM2 (0.66) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| US-20180118684-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| EP-1786773-B1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RES TECH LTD (GB) | 2017-03-01 | — | — | EP | disclosed |
| US-20160355478-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9358222-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-07 | — | — | US | disclosed |
| EP-2960233-A1 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2015-12-30 | — | — | EP | disclosed |
| US-20140194486-A1 | THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-07-10 | — | — | US | disclosed |
| US-8618158-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-12-31 | — | — | US | disclosed |
| US-8258175-B2 | Prodrug; novel series of compounds which inhibit the MDM2-p53 interaction and have in vitro activity exerting an anti-tumour effect; cancer | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20110224274-A1 | New Therapeutic Agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-09-15 | — | — | US | disclosed |
| EP-2315749-A2 | NEW THERAPEUTIC AGENTS | Cancer Research Technology Limited (GB) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009156735-A2 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-30 | — | — | WO | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1786773-A1 | ISOINDOLIN-1-ONE DERIVATIVES | Cancer Research Technology Limited (GB) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006024837-A1 | ISOINDOLIN-1-ONE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194486-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | MDM2 2/4885 |
| US-20080261917-A1 | Isoindolin-1-One Derivatives | HCN3, NHERF1, SIGMAR1 | MDM2 1568/4885 |
| US-20110224274-A1 | New Therapeutic Agents | TP53, MDM2, TP53BP1 | MDM2 2/4885 |
| US-20180118684-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | MDM2 2/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | MDM2 2/4885 |
| US-20160355478-A1 | THERAPEUTIC AGENTS | TP53, MDM2, TP53BP1 | MDM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.